AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.565
-0.055 (-1.52%)
Nov 26, 2025, 12:06 PM EST - Market open
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $8.96M in the quarter ending September 30, 2025, with 37.62% growth. This brings the company's revenue in the last twelve months to $35.33M, up 7.17% year-over-year. In the year 2024, AbCellera Biologics had annual revenue of $28.83M, down -24.17%.
Revenue (ttm)
$35.33M
Revenue Growth
+7.17%
P/S Ratio
30.50
Revenue / Employee
$59,270
Employees
596
Market Cap
1.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABCL News
- 4 days ago - AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 16 days ago - AbCellera Appoints Dr. Stephen Quake to its Board of Directors - Business Wire
- 18 days ago - AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - AbCellera Reports Q3 2025 Business Results - Business Wire
- 7 weeks ago - AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 - Business Wire
- 7 weeks ago - AbCellera Biologics: Entering Growth Phase After A Pause - Seeking Alpha
- 2 months ago - AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 2 months ago - AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer - Business Wire